ISIman Seyhoun

Iman Seyhoun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Iman Seyhoun has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Bahram Chahardouli

    Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Javad Verdi

    Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Maryam Barkhordar

    Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Mohammad Ahmadvand

    Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.

    2 shared publications
  • Nasim Vousooghi

    Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Abolfazl Iranikhah

    Department of Gastroenterology, Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran

    1 shared publication

Latest Publications

  • Open Access

    Exosome-functionalized scaffolds for bone regeneration: a systematic review and meta-analysis

    by Asrin Emami, Fatemeh Ashrafi, Maryam Rahnama, Metanat Safari, Iman Menbari Oskouie, Iman Seyhoun, Arsalan Jalili

    Background: Exosome/small extracellular vesicle (sEV)-functionalized scaffolds represent a promising cell-free strategy for bone regeneration by combining biomaterial structural support with sustained EV-mediated osteogenic, angiogenic, and immunomodulatory signaling. Methods: A PRISMA 2020–compliant systematic review and meta-analysis was conducted, prospectively registered in the PROSPERO database (registration number: CRD420251248297), to synthesize preclinical evidence from animal bone defect models and complementary in vitro studies published between January 1, 2010, and August 28, 2025. PubMed/MEDLINE, Scopus, Web of Science Core Collection, Embase, and Google Scholar were searched for English-language preclinical studies evaluating EV/sEV-functionalized scaffolds, including studies describing these vesicle preparations as exosomes. Animal bone defect models were considered for quantitative synthesis, while in vitro studies provided complementary mechanistic evidence. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the SYRCLE tool. Random-effects meta-analyses pooled standardized week-8 outcomes as Hedges’ g. Results: Forty-one studies were included in the qualitative synthesis and 24 were eligible for the meta-analysis. Most investigations combined in vitro and in vivo experiments, were conducted in China, and used rat models, particularly critical-sized calvarial defects. Mesenchymal stem cell-derived exosome/sEV preparations, frequently described as exosomes by the original studies, predominated, particularly those derived from bone marrow MSCs. Physical adsorption and hydrogel encapsulation were the most commonly reported incorporation strategies. At week 8, exosome/sEV-functionalized scaffolds significantly improved bone volume fraction (BV/TV; 17 studies; standardized mean difference (SMD) [Hedges’ g]=6.00, 95% CI 4.19–7.81) and bone mineral density (BMD; 7 studies; Hedges’ g=5.27, 95% CI 2.95–7.60), although substantial heterogeneity remained. Conclusion: Exosome/sEV-functionalized scaffolds were associated with improvements in quantitative radiological outcomes, with complementary qualitative evidence from histological assessments. However, interpretation of these findings is limited by methodological variability and heterogeneity among preclinical studies. Standardized reporting, improved randomization/blinding, and large-animal validation are needed to refine effect estimates before clinical translation.

  • Open Access

    Metabolomics changes in premature ovarian insufficiency: a systematic review

    by Hediye Gholamshahi, Mohammad Mahdi Dehnavi, Fatemeh Chinisaz, Azadeh Aletaha, Iman Seyhoun, Masoumeh Majidi Zolbin

  • Open Access

    Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review

    by Shirin Tavakoli, Maryam Samareh-Salavati, Mahshid Akhavan Rahnama, Shahrokh Abdolahi, Ali Hassanzadeh, Zeinab Ghazvinian, Javad Verdi, Nasim Vousooghi, Saba Manoochehrabadi, Bahram Chahardouli, et al.

    Hepatocellular carcinoma remains a major healthcare burden worldwide and is predicted to be the cause of death of 1.3 million people in 2040. Most HCC patients are diagnosed in advanced stages, leading to a poor prognosis. The development of targeted immunotherapies is essential to address this unmet clinical challenge. Natural killer (NK) cells have emerged as a promising cell-based therapeutic approach for treating solid tumors. NK cells have the distinctive ability to identify and destroy cancer cells without requiring prior sensitization. Here, we discuss potential approaches, developing strategies, and current challenges of NK cell therapy reported completely. In addition, advancements in immunotherapy, including adoptive NK cell therapy, and the strategies to boost NK cell function against HCC such as cytokine-based treatments, immune checkpoint inhibitors, vaccine-based approaches, genetic delivery, non-coding RNAs, antibody-based methods, and natural agents have been discussed. This comprehensive study provides a unique perspective by integrating recent findings on the differential impact of NK cells on HCC. We highlight the latest advances in NK cell engineering and immune checkpoint modulation, presenting a comparative analysis of therapeutic strategies. Furthermore, we critically assess the translational challenges associated with NK cell-based therapies, particularly focusing on their limited in vivo persistence and tumor immune evasion strategies.


  • Open Access

    Safety and feasibility of blockade of NK group-2 member-A receptor in natural killer cells combined with cetuximab antibody in patients with advanced gastric adenocarcinoma

    by Maryam Samareh Salavatipour, Shirin Tavakoli, Maryam Barkhordar, Iman Seyhoun, Nasim Vousooghi, Mohammad Vaezi, Afshin Ghaderi, Tahereh Bakhtiari, Ardeshir Ghavamzadeh, Javad Verdi, et al.

    Purpose: Blocking of inhibitory receptors such as NK group-2 member-A (NKG2A) enhances tumor immunity of natural killer (NK) cells. Additionally, antibody-dependent cellular cytotoxicity (ADCC) is an important cytotoxic modality of action of NK cells, which act as a functional bridge between innate and adaptive immunity. Here, we investigated the safety and feasibility of anti-NKG2A antibody-pretreated NK cells combined with IgG1 antibody (cetuximab) in patients with advanced gastric adenocarcinoma (GAC). Method: In this pilot study, treatment was initiated with cetuximab-based chemotherapy, followed by three times adoptive administration of anti-NKG2A pretreated NK cells (at doses 7×108 cells/injection) at 5-day intervals in three unresectable and locally advanced GAC patients who enrolled regarding vital signs and clinical characteristics. The clinical signs, laboratory parameters, and CTCAE (Common Terminology Criteria for Adverse Events) were documented for a safety and feasibility assessment. Results: The expanded cells were confirmed to be enriched in NK cells with high expression of CD56 (88.1%) and low expression of NKG2A (0.22%). The combination NK cell therapy was well tolerated, with transient adverse events. All patients were alive at the last follow-up (24 weeks). All patients showed overall decreases in tumor size and CA 19–9 level 4 weeks after combination therapy. However, two patients showed progressive disease (PD) after 12 weeks and the level of CA19-9 was increased in all three patients after 24 weeks. Conclusion: In conclusion, this study demonstrated the safety and feasibility of infusing high doses of anti-NKG2A pretreated NK cells combined with cetuximab in patients with GAC.

  • Open Access

    Cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal stem cells: a phase 1 clinical trial

    by Mahshid Saleh, Amir Abbas Vaezi, Rasoul Aliannejad, Amir Ali Sohrabpour, Seyedeh Zahra Fotook Kiaei, Mahdi Shadnoush, Vahid Siavashi, Leila Aghaghazvini, Batoul Khoundabi, Shahriyar Abdoli, et al.

    Background: Mesenchymal stem cells (MSCs) have received particular attention because of their ability to modulate the immune system and inhibit inflammation caused by cytokine storms due to SARS-CoV-2. New alternative therapies may reduce mortality rates in patients with COVID19. This study aimed to assess the safety and efficacy of injecting intravenous Wharton’s jelly-derived MSCs in patients with COVID-19 as a treatment. Methods: In this study, five patients with severe COVID-19 were treated with Wharton’s jelly-derived mesenchymal stem cells (150 × 106 cells per injection). These patients were subject to three intravenous injections 3 days apart, and monitoring was done on days 0, 3, 6, and 14 in routine tests, inflammatory cytokines, and flow cytometry of CD4 and CD8 markers. A lung CT scan was performed on base and days 14 and 28. In addition, IgM and IgG antibodies against SARS-CoV-2 were measured before and after treatment. Results: The results showed that IL-10 and SDF-1 increased after cell therapy, but VEGF, TGF-β, IFN-γ, IL-6, and TNFα decreased. Routine hematology tests, myocardial enzyme tests, biochemical tests, and inflammation tests were performed for all patients before and after cell therapy on base and days 3, 6, and 14, which indicated the improvement of test results over time. COVID-19 antibody tests rose in 14 days after WJ-MSC injection. The total score of zonal involvement in both lungs was improved. Conclusions: In patients, the trend of tests was generally improving, and we experienced a reduction in inflammation. No serious complications were observed in patients except the headache in one of them, which was resolved without medication. In this study, we found that patients with severe COVID-19 in the inflammatory phase respond better to cell therapy. More extensive clinical trials should be performed in this regard. Trial registration: IRCT, IRCT20190717044241N2. Registered April 22, 2020.


  • Open Access

    Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review

    by Faezeh Hosseinzadeh, Javad Verdi, Jafar Ai, Saieh Hajighasemlou, Iman Seyhoun, Frzad Parvizpour, Fatemeh Hosseinzadeh, Abolfazl Iranikhah, Sadegh Shirian

    High prevalence of hepatocellular carcinoma (HCC) and typically poor prognosis of this disease that lead to late stage diagnosis when potentially curative therapies are least effective; therefore, development of an effective and systematic treatment is an urgent requirement. In this review, several current treatments for HCC patients and their advantages or disadvantages were summarized. Moreover, various recent preclinical and clinical studies about the performances of “two efficient agents, sorafenib or natural killer (NK) cells”, against HCC cells were investigated. In addition, the focus this review was on the chemo-immunotherapy approach, correlation between sorafenib and NK cells and their effects on the performance of each other for better suppression of HCC. It was concluded that combinational therapy with sorafenib and NK cells might improve the outcome of applied therapeutic approaches for HCC patients. Finally, it was also concluded that interaction between sorafenib and NK cells is dose and time dependent, therefore, a careful dose and time optimizing is necessary for development of a combinational immune-cell therapy.